Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037566 | 0.93 | MCHR1 (0.45) | MCHR1SSTR5KMT2ATEAD1HRH3 | |
| SCHEMBL20037701 | 0.88 | MCHR1 (0.36) | MCHR1SSTR5KMT2A | |
| SCHEMBL20037572 | 0.86 | MCHR1 (0.39) | MCHR1 | |
| SCHEMBL3859413 | 0.85 | LMNA (0.48) | MCHR1TEAD1HRH3 | |
| SCHEMBL20037697 | 0.83 | DCPS (0.39) | SSTR5KMT2A | |
| SCHEMBL18291606 | 0.82 | PIK3CA (0.45) | MCHR1SSTR5KMT2AHRH3 | |
| SCHEMBL12099306 | 0.79 | ACHE (0.54) | KMT2AHRH3 | |
| SCHEMBL1994806 | 0.79 | HRH3 (0.39) | HRH3 | |
| SCHEMBL20037567 | 0.78 | HRH3 (0.41) | KMT2AHRH3 | |
| SCHEMBL31072985 | 0.78 | CCR5 (0.40) | SSTR5KMT2ATEAD1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | MCHR1 4511/4885SSTR5 2397/4885KMT2A 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.